IKEMA: sarclisa + KdExplore sarclisa + Kd
mPFS: Not yet reached (NR) with sarclisa + Kd (n=179) vs 20.27 months with Kd alone (n=123), HR=0.548 (95% CI: 0.37, 0.82; P=0.0032)1
ICARIA-MM: sarclisa + PdExplore sarclisa + Pd
mPFS: 11.53 months with sarclisa + Pd (n=154)
vs 6.47 months with Pd alone (n=153), HR=0.596
(95% CI: 0.44, 0.81; P=0.0010)1
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend isatuximab-irfc (sarclisa) for previously treated multiple myeloma2
- In combination with pomalidomide and dexamethasone (Preferred, Category 1)
- In combination with carfilzomib and dexamethasone
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
mPFS=median progression-free survival; NCCN=National Comprehensive Cancer Network; PFS=progression-free survival.